

Takaomi Kessoku

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5070549/publications.pdf>

Version: 2024-02-01

36
papers

1,297
citations

687220

13
h-index

414303

32
g-index

44
all docs

44
docs citations

44
times ranked

1849
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016, 150, 626-637.e7.	0.6	628
2	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. <i>PLoS ONE</i> , 2016, 11, e0146337.	1.1	135
3	Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. <i>Scientific Reports</i> , 2016, 6, 22251.	1.6	67
4	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. <i>BMC Gastroenterology</i> , 2017, 17, 96.	0.8	65
5	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , 2022, 6, 120-132.	2.0	60
6	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001990.	1.2	53
7	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 1022-1032.	2.3	49
8	Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. <i>PLoS ONE</i> , 2017, 12, e0175626.	1.1	41
9	The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8161.	1.8	29
10	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	1.4	26
11	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 996-1007.	3.7	22
12	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 872-880.	1.8	19
13	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. <i>Hepatology Communications</i> , 2022, 6, 2273-2285.	2.0	17
14	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 181-186.	0.6	13
15	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100516.	0.5	11
16	Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial. <i>Cancers</i> , 2022, 14, 2112.	1.7	11
17	Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. <i>BMJ Open</i> , 2020, 10, e037961.	0.8	6
18	Learning Curve of Endoscopic Retrograde Cholangiopancreatography Using Single-Balloon Enteroscopy. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2882-2890.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Expert Consensus Document: Diagnosis for Chronic Constipation with Faecal Retention in the Rectum Using Ultrasonography. <i>Diagnostics</i> , 2022, 12, 300.	1.3	5
20	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <i>Contemporary Clinical Trials</i> , 2018, 69, 40-47.	0.8	4
21	Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. <i>Trials</i> , 2020, 21, 453.	0.7	4
22	Development of a list of competencies and entrustable professional activities for resident physicians during death pronouncement: a modified Delphi study. <i>BMC Medical Education</i> , 2022, 22, 119.	1.0	4
23	Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms. <i>Internal Medicine</i> , 2023, 62, 159-167.	0.3	4
24	â€œGuidebook on Doctorsâ€™ Behaviors for Death Diagnosis Created by Community Healthcare Providersâ€™ Changed Residentsâ€™ Mind for Death Diagnosis. <i>Journal of Palliative Care</i> , 2020, , 082585972095169.	0.4	3
25	Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study. <i>Diabetology International</i> , 2018, 9, 189-195.	0.7	2
26	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. <i>Oncologist</i> , 2021, 26, e1862-e1869.	1.9	2
27	Evaluation of a combination protocol of CT-first triage and active telemedicine methods by a selected team tackling COVID-19: An experimental research study. <i>Journal of Infection and Public Health</i> , 2021, 14, 1212-1217.	1.9	2
28	Development and Validation of the Death Pronouncement Burden Scale for Oncology Practice. <i>Palliative Medicine Reports</i> , 2022, 3, 39-46.	0.4	2
29	Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	2
30	Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. <i>BMJ Open</i> , 2022, 12, e060335.	0.8	2
31	Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. <i>Frontiers in Oncology</i> , 2020, 10, 555963.	1.3	1
32	Naldemedine for opioid-induced constipation in patients receiving palliative care: A real-world registry study (Phase-R OIC Study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11582-11582.	0.8	1
33	Tapentadol Safety and Patient Characteristics Associated with Treatment Discontinuation in Cancer Therapy: A Retrospective Multicentre Study in Japan. <i>Pain and Therapy</i> , 2021, 10, 1635-1648.	1.5	1
34	Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100958.	0.5	1
35	A Survey of Palliative Care Ward Nursesâ€™ Awareness, Feelings, Behavioral Intentions and Hands-on Experience in Supporting an Environment in Which End-of-life Cancer Patients Nurture Love with Their Partners. <i>Palliative Care Research</i> , 2021, 16, 153-162.	0.0	0
36	Report of Effect on the Medical Education of the Guidebook about the Behaviors of Physicians on the Death Pronouncement. <i>Palliative Care Research</i> , 2017, 12, 906-910.	0.0	0